Ganitumab  (Synonyms: AMG 479; Human Anti-IGF1R Recombinant Antibody)

Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Ganitumab (AMG 479; 0.032-500 nM; 10 min; CT26 cells) binds mIGF1R and inhibits IGF1- and IGF2-mediated activation of mIGF1R^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ganitumab (AMG 479; 1 mg/dose; i.p; Naïve and tumor-bearing mice) inhibits IGF1-induced activation of mIGF1R in murine lungs^[1].
Ganitumab (300 μg/dose; i.p.; female athymic nude mice) reduces peripheral blood neutrophils^[1].
Ganitumab (300 μg/dose; i.p.; male athymic nude mice) causes impaired glucose tolerance in male mice and increases serum levels of mGH, mIGF1 and mIGFBP3^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

905703-97-1

Liquid

Colorless to light yellow

[Ganitumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Loaded IGF-I R Protein, Human (HEK293, His-Avi, HY-P78458) on AHC2 biosensor, can bind Ganitumab with an affinity constant of 8.072E-10 M as determined in BLI assay.

• [1]. Moody G, et, al. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. J Endocrinol. 2014 Mar 17;221(1):145-55.  [Content Brief]